Alimta To Replace Taxotere As Standard For Non-Small Cell Lung Cancer – Lilly
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly expects its non-small cell lung cancer therapy Alimta (pemetrexed) to replace Taxotere (docetaxel) as the standard of care in the second-line setting, Exec VP-Pharmaceutical Operations John Lechleiter said Jan. 11 at the J.P. Morgan health care conference in San Francisco